Verdict: KEEP

No informational edge at $160B cap with 35 analysts. Zero rows where P_us differs from P_market. Burden of proof is on removal and ISRG doesn't clear it.

Factor Decomposition

iev regress ISRG (trailing 251d)

SPY    +0.91    32.6% of variance
XLV    +0.38     9.8% of variance
MTUM   +0.03     1.3% of variance
Idio             56.3% of variance

alpha = -20.3%   sigma_idio = 25.5%   Idio SR = -0.80

56% idio variance, below the 75% target. ISRG is ≈44% factor-driven (market beta + healthcare sector). But MTUM beta is approximately zero. No anti-momentum signal. This differentiates ISRG from our factor-mismatch removes (MAR -0.57, CMCSA -0.56, CSX -0.46, SBUX -0.45, CTAS -0.36).

The trailing alpha of -20.3% is backward-looking. It captures the repricing from 75x to 57x P/E that already happened. Forward idio alpha at this saturation level should be approximately zero.

Financials (verified against 10-K filed 2026-02-03)

Revenue (10-K lines 6660-6668): $10.065B, +20.5% YoY. Instruments & Accessories $6.019B (+19%), Systems $2.474B (+26%), Service $1.572B (+20%). Recurring revenue 84% of total (10-K line 6768).

Margins (10-K lines 7747-7773): Total gross margin 66.0% (down from 67.5%). Service gross margin compressed 440 bps to 64.6% due to higher dV5 servicing costs, unfavorable repair mix, and facility depreciation (10-K lines 6823-6827). Operating margin expanded 120 bps to 29.3% on SGA leverage. Net income $2.856B, diluted EPS $7.87 (+22.6%).

2026 guidance (transcript lines 76-81): Procedure growth 13-15%. Pro forma gross margin 67-68% (flat). Tariff impact 120 bps of net revenue (vs 65 bps in 2025). Opex growth 11-15% including distributor acquisition expenses.

Capital (transcript lines 19, 57): Cash and investments $9.0B. Zero debt. FCF $2.5B. Buyback: $2.3B at avg $478/share, $1.7B authorization remaining (10-K line 5466). Fortress.

What the Market Is Pricing

Sell-Side

24 Buy / 9 Hold / 2 Sell. Mean target $605 (+34%). Citi upgraded to Buy Mar 11. UBS Neutral at $550. Consensus EPS estimate for Q1: $2.13 against 4 straight beats averaging +12.7%.

Options Market (as of 2026-03-27)

The money tells a different story than the ratings.

Implied earnings move: +/-7.6%. Derived from IV step-up across the Apr 21 earnings date: Apr 17 expiry (39.8% IV) vs Apr 24 expiry (48.6% IV). Brackets $419-$487.

Bifurcated positioning. Apr 24 (earnings week, 561 OI): P/C = 0.50, bullish. Small speculative call buying. May 15 (post-earnings, 11,047 OI): P/C = 3.88, very bearish. 20x the OI. The put wall: $430 strike 2,059 contracts, $420 strike 1,500, $405 strike 1,577, $500 strike 1,264. Roughly 6,400 puts across four strikes, ≈$280M+ notional hedged.

Interpretation: Institutions are LONG and HEDGED, not directionally short. They own ISRG and are paying 45-49% IV (double 24.6% realized vol) for downside protection through earnings. The put wall at $420-430 creates a gamma floor: dealers short those puts must buy stock as it drops, creating mechanical support. The insurance being bought makes the insured event less likely.

IV rank 67-74th percentile. Options are expensive relative to history. Vol sellers are compensated, vol buyers are overpaying. Generic vol-selling edge, not ISRG-specific.

Relative Performance

ISRG has underperformed QQQ by -28.2% over 1 year, -1.9% over 1 month, -2.0% over 1 week. That's massive idiosyncratic underperformance for a name with 20% revenue growth. The market has been de-rating ISRG for 12 months while fundamentals held up. Message: the market doesn't believe 13-15% procedure growth justifies 57x P/E. The deceleration from 21% is treated as structural, not episodic.

Where the Market Might Be Wrong (But We Can't Prove It)

1. Sell-side target anchoring. Mean target $605 implies re-rating to ≈52x forward P/E. Sell-side models rarely permanently de-rate growth names. This is a known systematic bias, not an insight.

2. Service margin isn't transient. dV5 was 57% of Q4 placements and growing. 10-K line 6823: "higher manufacturing and servicing costs" for dV5, language consistent with structural not cyclical. If another 200 bps of service GM compression materializes in FY26, that's ≈$30M impact. Immaterial at $160B cap.

3. Competitive moat overestimation. Hugo cleared FDA Dec 2025 (urology). Ottava submitted de novo Jan 2026 (general surgery). Credible alternatives compress multiples before they compress earnings. The 75x-to-57x repricing may partly reflect this, or may have further to go.

All three are "the market could be slightly wrong." None are "the market IS wrong and here's the catalyst." No catalyst, no trade.

Procedure Volumes (10-K lines 6197-6245)

Worldwide total: ≈3.1M+ procedures (+18%). US +15%, OUS +23%. OUS general surgery is the fastest-growing segment (+31%), driven by colorectal and hernia. US bariatric declined high-single digits (GLP-1 impact, 10-K line 6713). Ion procedures +44% in Q4 (small base). System utilization up 3% (4% in Q4), reflecting dV5 efficiency gains.

11,106 installed systems (10-K line 6057). 1,231 dV5 systems as of Dec 31 (10-K line 5599). 10,000+ surgeons trained (transcript line 41). 303 of 532 Q4 placements were dV5 (57%). Force Feedback instruments not yet in full supply (transcript line 145), MIA+ subscription monetization starts ~Q2 2026 (transcript line 143).

8-Ks (Last 6 Months)

2026-03-02: Completed acquisition of da Vinci/Ion distribution in Italy, Spain, Portugal, Malta, San Marino. ≈250 employees transferred, 470+ installed systems. Distributor-to-direct = margin accretive long-term. Part of 11-15% opex growth guidance.

2026-01-22: Q4/FY2025 earnings release.

2026-01-14: Preliminary Q4/FY2025 results (JPM Healthcare Conference).

2025-12-18: CDO role change (Brian Miller to Head of Digital & AI Strategy). Reorg, not departure.

2025-10-21: Q3 2025 earnings release.

No going concern language. No executive departures. No adverse regulatory actions.

Tariff Exposure (10-K lines 5687-5696)

I&A is 60% of revenue. Manufactured in Mexicali, Mexico. USMCA-qualifying, not subject to US import tariffs "to date" (10-K line 5692). The 120 bps 2026 tariff guidance comes from German endoscopes (10-K line 6802) and Chinese raw materials (10-K line 5696). USMCA revocation is a tail risk (≈5% probability) affecting all cross-border manufacturers, not ISRG-specific.

Competitive Position

Medtronic Hugo: FDA cleared Dec 2025, urologic procedures only. 80+ systems outside US. Zero US installed base, no training infrastructure, no recurring revenue flywheel. Real competitor but years behind in ecosystem. Not a 15-week concern.

J&J Ottava: De novo FDA submission Jan 7, 2026 for general surgery. Earliest clearance mid-to-late 2026, commercial availability 2027+. Not in our window.

China domestic: Multiple companies with Xi-like architectures. Provincial preference for local suppliers. Win ratio declining per Q4 transcript. China is <5% of revenue.

Moat: 11,106 installed systems consuming proprietary I&A. 10,000+ trained surgeons. 84% recurring revenue at ≈$1,850/procedure. 5,600+ patents. 200,000+ patient meta-analysis (CONVERSION Study, Annals of Surgery). Network effects across surgeon training, hospital credentialing, payer relationships.

Stapler Recall (March 2026)

8mm SureForm 30 Gray Reload recall, one death reported, four injuries, March 11, 2026. No 8-K filed (not deemed material). One SKU among hundreds. Stock sold off ≈5% around that date. Not systemic.

Confidence: MEDIUM. Cannot verify death/injury counts from primary SEC sources. FDA database action only.

Risk Assessment (15-Week Window)

RiskPImpactNotes
Q1 miss + guide-down≈15%-10-15%4 straight beats makes unlikely. Service margin and tariff are real headwinds.
USMCA revocation≈5%-5-10%Tail. Would affect all Mexico manufacturers.
Stapler recall escalation≈10%-3-5%Would need pattern beyond one SKU.
ACA/Medicaid changes≈20%-2-4%Slow to flow through. Most ISRG procedures not elective.
Broad medtech compression≈25%-5-10%Beta risk. Cancels in hedged basket.
Hugo US commercial launch≈30%-1-2%Urologic only. Symbolic in 15 weeks.

No risk individually clears the burden of proof for removal.

Basket Impact

At 0.94% selectable weight: earnings exposure is +/-7.1 bps. Beta leakage (1.68 vs QQQ 1.0) contributes 0.64% of market return through the hedge. Both are noise at this weight.

The trailing idio alpha of -20.3% annualized implies ≈5.5 bps of drag over 15 weeks if the rate continues. But the repricing appears largely complete (16% of 52-week range, RSI 24.8) and forward idio alpha should converge toward zero absent new information.

Removing ISRG and eating a 10% oversold bounce costs 9.4 bps. Keeping and absorbing another 10% decline costs 9.4 bps. Asymmetry slightly favors keep given oversold technicals, earnings catalyst, and fundamental strength.

Monitor

Q1 earnings April 21. Watch for:

  • Procedure growth below 13% guidance floor
  • Service margin compression beyond -440 bps
  • Any change in USMCA qualifying language
  • Stapler recall pattern (additional SKUs)

If miss + guide-down to <13% procedures: reconsider for removal.

Sources

All financials verified against ISRG 10-K filed 2026-02-03 with line references. Transcript data from Q4 2025 earnings call (2026-01-22) with line references. Market data from yfinance as of 2026-03-27. Factor regression via iev regress ISRG (trailing 251d). 8-Ks from EDGAR (2025-10 through 2026-03).